Market Research Report
Precision Medicine Software - Global Market Outlook (2017-2026)
|Published by||Stratistics Market Research Consulting||Product code||825538|
|Published||Content info||171 Pages
Delivery time: 2-3 business days
|Precision Medicine Software - Global Market Outlook (2017-2026)|
|Published: March 1, 2019||Content info: 171 Pages||
According to Stratistics MRC, the Global Precision Medicine Software market is accounted for $0.87 billion in 2017 and is expected to reach $2.72 billion by 2026 growing at a CAGR of 13.5%. Some of the factors influencing the market growth are increase in the number of cancer patients, rising government funding in precision medicine initiatives and technological advancements in applications of big data technologies. However, the lack of skilled IT professionals in healthcare and the high cost of deployment are hindering the market growth.
Based on application, the oncology segment commanded significant market growth during the predicted period due to increased funding in cancer research and the rising occurrence of cancer. In addition, increase genomics-based clinical trials of targeted agents and immunotherapy is also fuelling the segment growth during the forecast period. Biomarkers have other specific applications in the field of oncology.
By geography, North America is anticipated to dominate the global market. The regional market growth is majorly driven by the rising HCIT investments in this region and increasing digitalization.
Some of the key players in the Precision Medicine Software market include 2bprecise, LLC, Gene42, Inc., Syapse, Inc., Human Longevity, Inc., Fabric Genomics, Inc., Translational Software Inc., Allscripts, Sophia Genetics Sa, Roper Technologies, Qiagen, Lifeomic Health, LLC and Pieriandx, Inc.
Delivery Modes Covered:
End Users Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances